NASDAQ:EVGN • IL0011050551
The current stock price of EVGN is 0.8207 USD. In the past month the price decreased by -20.32%. In the past year, price decreased by -42.08%.
ChartMill assigns a fundamental rating of 2 / 10 to EVGN. EVGN has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months EVGN reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 88.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.54% | ||
| ROE | -240.72% | ||
| Debt/Equity | 1.62 |
7 analysts have analysed EVGN and the average price target is 2.55 USD. This implies a price increase of 210.71% is expected in the next year compared to the current price of 0.8207.
For the next year, analysts expect an EPS growth of 79.67% and a revenue growth -62.81% for EVGN
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 396.512B | ||
| AMGN | AMGEN INC | 16.63 | 202.199B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.492B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 119.063B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.713B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.834B | ||
| INSM | INSMED INC | N/A | 34.336B | ||
| NTRA | NATERA INC | N/A | 30.104B | ||
| BIIB | BIOGEN INC | 12.62 | 28.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.691B |
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
EVOGENE LTD
13 Gad Feinstein Street, Park Rehovot
Rehovot 7414002 IL
CEO: Ofer Haviv
Employees: 117
Phone: 97289311900
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
The current stock price of EVGN is 0.8207 USD. The price decreased by -7.54% in the last trading session.
EVGN does not pay a dividend.
EVGN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
EVOGENE LTD (EVGN) currently has 117 employees.
EVOGENE LTD (EVGN) will report earnings on 2026-03-05, before the market open.
You can find the ownership structure of EVOGENE LTD (EVGN) on the Ownership tab.